22nd Century Group To Present Its Modified Risk Tobacco Product Application To FDA

Source from:  GlobeNewswire 08/13/2020

22nd Century Group, Inc., a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes.

“We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group. “This public meeting is an important milestone for 22nd Century Group and for adult smokers who want to reduce their exposure to nicotine.

“We believe that the authorization of our MRTP application would support the FDA’s goal to advance and implement a product standard to reduce the level of nicotine in all cigarettes sold in the U.S. to non-addictive levels. Authorization of our MRTP application for our proprietary VLN® cigarettes also would be further proof of the scientific and technical achievability of the FDA’s proposed product standard to improve public health and save millions of lives.”  Enditem